Published in final edited form as:

J Genet Syndr Gene Ther. 2012 May 25; Suppl 1: . doi:10.4172/2157-7412.S1-011.

Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery

Christopher D. Porada* and Graça Almeida-Porada

Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA

Abstract

Hemophilia A represents the most common inheritable deficiency of the coagulation proteins. Current state-of-the-art treatment consists of frequent prophylactic infusions of plasma-derived or recombinant FVIII protein to maintain hemostasis, and has greatly increased life expectancy and quality of life for many hemophilia A patients. This treatment approach is, however, far from ideal, due to the need for lifelong intravenous infusions, the high treatment cost, and the fact that it is unavailable to a large percentage of the world's hemophiliacs. There is thus a need for novel treatments that can promise long-term or permanent correction. In contrast to existing protein based therapeutics, gene therapy offers to provide a permanent cure following few, or even a single, treatment. In the present paper, we review ongoing work towards this end, focusing on studies we have performed in a large animal model. Some of the key topics covered in this review include the unique opportunities sheep offer as a model system, the re-establishment and clinical and molecular characterization of a line of sheep with severe hemophilia A, the advantages and feasibility of treating a disease like hemophilia A in utero, and the use of Mesenchymal Stem Cells (MSC) as cellular delivery vehicles for the FVIII gene. The review finishes with a brief discussion of our recent success correcting ovine hemophilia A with a postnatal transplant with gene-modified MSC, and the limitations of this approach that remain to be overcome.

Hemophilia A and the Need for Better Treatments

Hemophilia A represents the most common inheritable deficiency of the coagulation proteins [1]. The severity of hemophilia A is traditionally based on plasma levels of FVIII, with persons exhibiting less than 1% normal factor ($< 0.01\text{IU/mL}$) being considered to have severe hemophilia, persons with 1–5% normal factor moderately severe, and persons with 5%–40% of the normal FVIII levels mild [2–4]. Up to 70% of hemophilia A patients present with the severe form of the disease, and suffer from frequent hemorrhaging, leading to chronic debilitating arthropathy, hematomas of subcutaneous connective tissue/muscle, and internal bleeding. Over time, the collective complications of recurrent hemorrhaging result in chronic pain, absences from school and work, and permanent disability [2]. Current state-of-the-art treatment consists of frequent prophylactic infusions of plasma-derived or recombinant FVIII protein to maintain hemostasis, and has greatly increased life expectancy and quality of life for many hemophilia A patients.

© 2012 Porada CD, et al.

*Corresponding author: Christopher D. Porada, Regenerative Medicine, Wake Forest Institute for Regenerative Medicine, Richard H. Dean Biomedical Building, 391 Technology Way, Winston-Salem, NC 27157-1083, USA, Tel: 336-713-1631; cporada@wakehealth.edu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This treatment approach is, however, far from ideal, due to the need for lifelong intravenous infusions and the high treatment cost. Moreover, this treatment is unavailable to a large percentage of the world's hemophiliacs, placing these patients at great risk of severe, permanent disabilities and life-threatening bleeds. Furthermore, even among the patients who are fortunate enough to have access to, and the financial means to afford, prophylactic FVIII infusions, approximately 30% will form FVIII inhibitors [5]. The formation of these inhibitors greatly reduces the efficacy of subsequent FVIII infusions, and can ultimately lead to treatment failure, placing the patient at risk of life-threatening hemorrhage. There is thus a significant need to develop novel, longer-lasting hemophilia A therapies.

In the past three decades, the remarkable progress in the understanding of the molecular basis of the disease, the identification and characterization of FVIII gene, structure, and biology has heightened the interest and feasibility of treating hemophilia A with gene therapy. In contrast to current protein-based therapeutics, lifelong improvement or permanent cure of hemophilia A is theoretically possible after only a single gene therapy treatment; indeed, several aspects of hemophilia A make it ideally suited for correction by gene therapy [6–14]. First, in contrast to many other genetic diseases, the missing protein (coagulation FVIII) does not need to be expressed in either a cell or tissue specific fashion to mediate correction. Although the liver is thought to be the primary natural site of synthesis of FVIII, expression of this factor in other tissues exerts no deleterious effects. As long as the protein is expressed in cells which have ready access to the circulation, it can be secreted into the bloodstream and exert its appropriate clotting activity. Second, even modest levels (3–5%) of FVIII-expressing cells would be expected to convert severe hemophilia A to a moderate/mild phenotype, reducing or eliminating episodes of spontaneous bleeding and greatly improving quality of life. Thus, even with the low levels of transduction that are routinely obtained with many of the current viral-based gene delivery systems, a marked clinical improvement would be anticipated in patients with hemophilia A. Conversely, even supra physiologic levels of FVIII as high as 150% of normal are predicted to be well tolerated, making the therapeutic window extremely wide [4]. Based on this knowledge, the American Society of Gene and Cell Therapy (www.ASGCT.org) recently provided NIH director, Dr. Francis Collins, with a roadmap of disease indications that it feels will be viable gene therapy products within the next 5–7 years. The hemophilias were identified as belonging to the most promising, “Target 10”, group of diseases.

Sheep as a Preclinical Model of Hemophilia A

A number of animal models have been developed to evaluate new methods of not only treatment of coagulation disorders, but also the prevention and treatment of inhibitor formation. Transient hemophilic rabbit models induced by infusion of plasma containing inhibitors have been used to evaluate the effect of different bypass products to factor VIII [15], but these models, while valuable for inhibitor studies, do not accurately recapitulate the human disease, precluding their use for gene therapy studies. Fortunately, dog models of hemophilia A with congenital deficiency [16,17] and mouse models obtained by gene targeting and knockout technology [18] are available to study FVIII function and gene therapy approaches for treating hemophilia A. Therapeutic benefit has been obtained in numerous studies using a variety of vector systems in the murine model [9,10,19–25], and phenotypic correction of hemophilia A in the dog has been achieved, but has proven to be far more difficult than in mice [26,27]. Despite promising results in both canine and murine models, however, no clinical gene therapy trial has shown phenotypic/clinical improvement of hemophilia A in human patients. This is in marked contrast to the recent clinical successes with gene therapy for hemophilia B [28]. The reasons for the disparity in the efficacy of gene therapy for treating hemophilia A versus B is not presently clear. Nonetheless, based on the disappointing results to-date, there is currently no active

hemophilia A clinical gene therapy trials, even though hemophilia A accounts for roughly 80% of all cases of hemophilia.

The difficulties seen thus far translating success in animal models into therapeutic benefit in human patients underscores the importance of preclinical animal models that both precisely mimic the disease process of hemophilia A, and closely parallel normal human immunology and physiology. To this end, between 1979 and 1982, a number of male offspring of a single white alpine ewe at the Swiss Federal Institute of Technology all died several hours post-partum due to severe bleeding from the umbilical cord [29–31]. Daughters and granddaughters of this ewe also gave birth to lambs exhibiting the same pathology. Investigation of the affected animals showed extensive subcutaneous and intramuscular hematomas. Spontaneous hemarthroses were also frequent, leading to reduced locomotion and symptoms of pain in standing up, restricting nursing activity. Stronger injuries that arose when animals were not placed in carefully controlled isolation resulted in heavy bleeding and intensive pain. Laboratory tests showed increased PTT, and FVIII levels (as assessed by aPTT) of about 1% of control animals. Replacement therapy with human FVIII (hFVIII) concentrate or fresh sheep plasma resulted in remission of disease and rapid clinical improvement.

Unfortunately, due to the expense and effort of maintaining these sheep, the Swiss investigators allowed the line to die out, saving only a few straws of semen prior to allowing this valuable resource to pass into extinction. We recently used a variety of reproductive technologies to successfully re-establish this line of hemophilia A sheep, we fully characterized both the clinical parameters and the precise molecular basis for their disease, and we developed a PCR-based screen for the disease-causing mutation that allows identification of affected animals in utero [32–37]. In similarity to mutations seen in many human patients [38], these animals possess a premature stop codon with a frame shift mutation. This is the only animal model of hemophilia A with this clinically relevant mutation-type, providing a unique opportunity to study therapies in this context. All ten animals to date have exhibited bleeding from the umbilical cord, prolonged tail and nail cuticle bleeding time, and multiple episodes of severe spontaneous bleeding including hemarthroses, muscle hematomas, and hematuria, all of which have responded to human FVIII concentrate. Just like human patients with severe hemophilia A, a hallmark symptom in these sheep is repeated spontaneous joint bleeds, which lead to chronic, debilitating arthropathies and reduced mobility. Importantly, chromogenic assays performed independently at the Blood Center of Wisconsin and Emory University revealed undetectable FVIII activity in the circulation of these sheep, explaining their severe phenotype.

In addition to the value of another large animal model of hemophilia A and the uniqueness of the mutation, sheep possess many characteristics that make them an ideal preclinical model for gene therapy. The first of these is the size. Sheep are fairly close in size to humans, weighing roughly 8lbs at birth and 150–200lbs as adults, likely obviating the need for scale-up of vector dose to move from experiments in sheep to trials in humans. This is in marked contrast to mice which are ~2800 times smaller than a typical human patient [39]. Of course, the large size of the sheep also carries with it the inherent cost to generate a sufficient volume/quantity of the novel therapeutic to be tested, making the sheep's size a double-edged sword. Secondly, sheep share many important physiological and developmental characteristics with humans; for example, the pattern of fetal to adult hemoglobin switching, and the naturally occurring changes in the primary sites of hematopoiesis from yolk sac to fetal liver and finally to the bone marrow near the end of gestation. In addition, in contrast to other large animal models such as dog and pig, sheep, like humans, typically have singleton or twin pregnancies rather than large litters of

offspring. It is thus not surprising that fetal sheep have been used extensively in the study of mammalian fetal physiology, and results obtained with this model have been directly applicable to the understanding of human fetal growth and development. Thirdly, sheep are out bred, and thus represent a wide spectrum of genetic determinants of the immune response, as do humans. As the immune response to both the vector and the vector-encoded FVIII are likely to play a key role in FVIII inhibitor formation (or lack thereof), this represents an advantage not found in most other models, with the possible exception of the dog, which could conceivably be out bred as well to achieve a broader genetic spectrum. This wider genetic spectrum could, however, also introduce greater animal-to-animal variability, potentially necessitating the use of larger numbers of animals per group to achieve statistical significance. In addition, the development of the sheep immune system has been investigated in detail [40–46], making sheep well suited for studying the immunological aspects of gene therapy for hemophilia A. Importantly, the large size of the sheep, their long life span (9–12 years), and their relative ease of maintenance and breeding make it possible to conduct the long-term studies in large numbers of animals that are necessary to fully evaluate the efficacy and safety issues related to gene therapy. For these reasons, we feel that the sheep are a particularly relevant model in which to examine gene therapy for hemophilia A. An additional unique advantage to using sheep to study hemophilia A treatment is that in sheep, like human, a large percentage of the Von Willebrand Factor (VWF) is found within platelets rather than free in plasma. This is in contrast to dog (in which Von Willebrand Factor (VWF) circulates free in plasma [47,48]), and makes the sheep an ideal large animal model in which to explore the use of platelet-targeted gene therapy for hemophilia A [14,49–51].

Rationale for Treating Hemophilia A before Birth

Even if the cost of current hemophilia A therapies were reduced sufficiently that the majority of patients could afford prophylactic FVIII infusions, these protein-based therapies would still require frequent, lifelong intravenous infusions, and would still be plagued by a high rate of treatment failure due to inhibitors. These problems could likely be circumvented by performing gene therapy before birth. Similarly, many of the hurdles that have thus far prevented gene therapy from curing patients with hemophilia A, or many of the other diseases that have been investigated, could likely be circumvented by performing in utero gene therapy. At the present time, hemophilia A, and many of the other diseases considered as candidates for gene therapy, can be diagnosed relatively early in gestation, making it feasible to begin devising methods for performing gene therapy in utero rather than waiting until after birth. Methods for accessing both the sheep and the human fetus are well established and clinically viable. Indeed, fetal transfusions and in utero stem cell-based therapies have safely been performed clinically for decades [52,53]. To date, 46 in utero transplants have been performed in human patients [54,55], for 14 different genetic disorders [53], and have proven that accessing the early human fetus multiple times, using a minimally invasive, ultrasound guided approach, poses minimal procedure-related risk [52–54,56–59]. Importantly, experience and knowledge gained from studies performed in the fetal sheep model were used to design and perform the first curative human in utero transplantation for X-SCID [56], highlighting the value of the fetal sheep model for not only developing clinically viable methodology, but also for predicting clinical outcome. Using these established clinically applicable methodologies to perform gene therapy early in gestation could correct hemophilia A prior to parturition, promising the birth of a normal healthy baby who, ideally, would require no further treatments. While most individuals with a family history of hemophilia A are encouraged to have prenatal screening, parents currently have only 2 choices following prenatal diagnosis of hemophilia A: termination of pregnancy or the birth of an affected child. The availability of a safe and effective in utero treatment would provide parents with a much-needed 3rd option that could promise the birth

of a healthy infant who required no further treatments. This opportunity would undoubtedly fuel much more widespread prenatal screening for HA. Although in vitro embryo screening and selection is a possible solution, this option is not widely available due to both its high cost and the lack of the required technology in developing countries. In utero gene therapy, in contrast, does not require any sophisticated equipment that would not already be in place for prenatal diagnosis. Indeed, several recent studies have now conclusively demonstrated the marked cost-effectiveness of prenatal screening for the hemophilias, even within developing third world countries [60–62]. Looking specifically at the US, according to the CDC, 320 babies are born with hemophilia A each year. The ability to correct this disease prior to birth could thus benefit the ~240 patients each year born into families with a history of hemophilia A. In addition to the clinical and financial advantages of performing gene therapy prior to birth, numerous aspects of the developing fetus make it a better recipient than the adult [63–65]. For example, due to their ability to integrate into the genome of the host cell, γ -retroviruses and lentiviruses have received a great deal of attention as gene delivery vectors, since transduction of a long-lived cell could provide lifelong therapy following a single administration. However, one of the main limiting factors to the successful application of these integrating vectors to in vivo gene therapy is the low level of initial transduction and the limited degree of expansion of transduced cells that occurs following gene therapy, since most cell populations in the adult are relatively quiescent unless injury is used to induce cell cycling. In the case of hemophilia A, the primary site of FVIII synthesis under normal physiologic conditions is the liver [66]. Yet, in a mature animal, it is estimated that only 1 in 10,000 hepatocytes is actively cycling at any given time [67], making it very difficult to obtain meaningful levels of gene transfer unless the gene delivery system mediates high efficiency transduction of quiescent cells, or injury such as partial hepatectomy is employed to induce cell division to enhance transduction and/or drive expansion of the limited numbers of transduced cells, as was done in dogs with hemophilia B [68]. In the fetus, the cells in all of the organs are actively cycling to support the continuous expansion that occurs throughout gestation. Thus, cells such as hepatocytes that are largely quiescent in the adult are far more mitotically active in the fetus. As such, these cells should be far more amenable to genetic correction with vectors requiring cell division. Furthermore, the active cycling of the cells in all of the organs to support the continuous expansion that occurs throughout gestation offers the possibility of achieving expansion of the gene-corrected cells during the remainder of gestation, such that initial transduction of even small numbers of target cells should lead to significant levels of gene-correction by birth. Importantly, even in the event of extremely high levels of transduction, supraphysiologic levels of FVIII as high as 150% of normal are predicted to be well tolerated, making the therapeutic window extremely wide [4]. Nevertheless, the sheep model provides a unique system in which to determine the potential for toxicity as a result of high-level expression of FVIII and optimize the dosing levels prior to considering attempting in utero clinical trials for hemophilia A. Remaining cognizant of the immune-aspects of hemophilia A treatment, it is important to note that, in addition to the ability to target cells which are largely refractory to transduction in the adult, unique immunologic advantages also exist for performing gene therapy in utero. There is a window of time in early immunologic development, before thymic processing of mature lymphocytes, during which the fetus is largely tolerant of foreign antigens. Exposure to foreign antigens during this period often results in sustained tolerance, which can become permanent if the presence of the antigen is maintained [69]. Given these unique immunological advantages suggest that in utero gene therapy would be an ideal approach for treating hemophilia A, since lifelong tolerance could theoretically be induced to FVIII. This would thus ensure that, even if in utero gene therapy was not curative, postnatal gene therapy or protein replacement could proceed safely without the risk of inhibitor formation.

Experimental in Utero Gene Therapy Studies

With the knowledge that performing gene therapy in utero would provide these advantages over existing post-natal approaches, we have spent the last two decades using the sheep model to investigate whether it is possible to exploit the highly proliferative state and relative immuno-naïveté of the early gestational fetus to achieve significant levels of gene transfer following a single intraperitoneal injection of a γ -retroviral vector [63,70–79]. This approach to in utero gene therapy is safe and technically simple, involving only a single ultrasound-guided injection into the peritoneum of the fetus, as early as 54 days of gestation (term: 145 days). This approach resulted in gene transfer levels as high as 5–6% within the hematopoietic system [73,78–80], a level that would certainly be therapeutic in hemophilia A. Importantly, these gene-marked hematopoietic cells persisted in these sheep over the course of 5 years of study [78,79], transgene-positive CD34⁺ cells could be detected in the bone marrow of these animals several years post in utero gene transfer [81], and bone marrow cells isolated from these recipients successfully engrafted the hematopoietic system of secondary fetal sheep recipients upon re-transplantation. These three pieces of data provide compelling evidence that this approach enabled us to successfully insert genes into true hematopoietic stem cells, suggesting this method could provide lifelong genetic correction. While transduction of clinically significant levels of HSC within these sheep following a single injection of vector into the peritoneal cavity hinted at the therapeutic potential of this simple approach to in utero gene therapy, the retroviral vectors we employed in these studies did not possess any type of targeting moiety which would restrict transduction to cells of the hematopoietic system. Not surprisingly, examination of other tissues of the recipients revealed that gene transfer was not limited to cells of the hematopoietic system, but had occurred in essentially all of the organs examined, including numerous cell types within the liver, lung, and brain [76,78,79,82]. Our results also revealed transduction of hepatocytes and hepatic endothelial cells (the cells thought to be the natural site of FVIII synthesis/production within the body) at levels that would likely be therapeutic in hemophilia A, and delineated the time period during gestation when hepatic transduction is optimal [76]. Concomitantly, in utero gene transfer studies performed by other investigators in sheep, rodent, and non-human primate models employing a variety of viral-based gene delivery vectors produced similar results [11,63,76–78,83–100], supporting the notion that this method could be used to deliver FVIII to the developing liver at levels that would convert patients with severe hemophilia A to a moderate or even mild phenotype [76]. Moreover, since tissue-specific expression is not necessary for FVIII, the transfer of this gene into a wide range of tissues with ready access to the circulation, followed by long-term expression, would greatly enhance the therapeutic potential of this approach for treating/curing hemophilia A. As discussed previously, one of the major hurdles hindering treatment of hemophilia A by factor replacement therapy is the formation of inhibitory antibodies that can occur in roughly 30% of patients with repeated FVIII infusions. While analyzing the tissues from the sheep that received in utero gene transfer, we noted that the thymus frequently exhibited transgene positivity by PCR [78, 79]. Given the pivotal role of the thymus during the development of the fetal immune system's ability to distinguish self from non-self, we undertook studies to ascertain the immunologic significance of the presence of these transgene-positive cells within the thymus. In our first set of studies, [101] we demonstrated that in utero gene transfer successfully induced durable immune tolerance to the vector-encoded β -galactosidase. This tolerance induction appeared to involve both cellular and humoral mechanisms, since both antibody responses and cellular responses to the transgene product were blunted in these animals even several years after in utero gene transfer. Further mechanistic studies demonstrated that performing in utero gene transfer early in gestation takes advantage of multiple tolerogenic avenues present in the fetus, since it results in the transduction of both thymic epithelial cells, which may promote induction of central immune tolerance, and cells of Hassall's corpuscles, which can instruct dendritic

cells to induce Tregs that can help maintain peripheral immune tolerance to the transgene products. These findings thus suggest that, even if not curative, in utero gene therapy would be ideal for hemophilia A, since lifelong tolerance could be induced to FVIII, thus overcoming the immune related hurdles that currently hinder post-natal treatment of this disease. Interestingly, the only studies that have thus far explored the possibility of performing in utero gene therapy for the treatment of the hemophilias have been aimed at correcting hemophilia B (factor IX deficiency) [11, 83, 84, 95–97, 99, 100, 102, 103], likely due to difficulties encountered in initial attempts to express FVIII as a transgene in the context of viral vectors [104]. Given the fact that patients with hemophilia A are >10x's as likely to develop inhibitory antibodies to the exogenous coagulation factor as patients with hemophilia B [105, 106], these studies thus leave unanswered the critical question of whether the ability to induce immune tolerance to marker gene products and FIX in utero will ultimately translate into the ability to induce tolerance to FVIII, given FVIII's higher inherent immunogenicity. Studies are ongoing in the sheep model to address this important issue. While gene transfer to multiple fetal tissues would be desirable for correcting a disease such as hemophilia A, that would benefit from widespread systemic release of a secreted transgene product, our analyses also revealed that the fetal reproductive tissues often contained proviral DNA, raising the troubling possibility that the developing germline had been modified as a result of in utero gene therapy. Since prior studies had demonstrated that both the embryonic germline [107–110] and isolated Primordial Germ Cells (PGC) [111] can readily be modified with murine retroviral vectors and pass the vector genetic material to subsequent generations in a Mendelian fashion, we rigorously addressed the risk to the germline in the fetal sheep model [70,77,87,112]. Although the fetal ovaries appeared to be unaffected by this approach to in utero gene transfer, we found that numerous cells within the developing testes were in fact modified, including small numbers of immature germ cells within the forming sex cords and the resultant sperm cells. Importantly, however, gene-modified germ cells were only observed in 2 of the 6 animals examined, and, in these two animals, the incidence of germ cell modification was roughly 1 in 6250, a frequency that is well below the theoretical level of spontaneous mutation within the human genome [113]. This low frequency of modification coupled with observations that genetic alterations to the germ cells may produce deleterious effects, placing them at a disadvantage during fertilization suggest that the likelihood that any genetic alterations present would be passed to subsequent offspring would be extremely unlikely. Intriguingly, other studies employing lentiviral vectors in non-human primates revealed modification of the female germline, but no effect on male germ cells [86]. Thus, the issue of germline safety will likely have to be investigated in more than one preclinical model, and the specific vector being considered for clinical use will have to be employed, in order to obtain an accurate assessment of the risk posed by the procedure. This multi-species data could then be presented to the FDA to determine whether whatever risk exists to the developing germline is outweighed by the potential benefits of intervening in utero.

The ultimate development of vectors that can target specific cell types following in vivo administration will ultimately make it possible to eliminate the risk of inadvertently modifying non-target cells, like those of the germline, following a direct vector injection approach to in utero gene therapy. Given the current absence of such vectors, and our desire to develop safer means of correcting hemophilia A and other diseases prior to birth, we have been exploring the possibility that mesenchymal stem cells can be used as vehicles to deliver exogenous genes to the developing fetus or neonate.

Mesenchymal Stem Cells (MSC) as Hemophilia A Therapeutics

In pioneering studies [114,115] performed over 30 years ago, Friedenstein demonstrated that fibroblastoid cells obtained from the bone marrow were capable of transferring the

hematopoietic microenvironment to ectopic sites, thus establishing the concept that the marrow microenvironment resided within the so-called marrow stromal cells. Years later, scientists began to explore the full potential of these microenvironmental cells, and results of these studies led to the realization that this population harbored cells with properties of true stem cells, now alternately referred to as marrow stromal cells or Mesenchymal Stem Cells (MSC) [116]. MSC only comprise roughly 0.001–0.01% of cells within the marrow [117], but can be passaged extensively in vitro without a loss of differentiative potential, making it possible to readily generate clinically relevant numbers of these cells [118]. Although much of the work to date has focused on MSC isolated from adult bone marrow, cells that appear phenotypically and functionally to be MSC have now been isolated by our group and others from numerous tissues, including brain, liver, lung, fetal blood, umbilical cord blood, kidney, and even liposuction material [119–126]. MSC have also been isolated from the amniotic fluid and the chorionic villi, making it possible to begin envisioning the use of autologous MSC as cellular therapeutics or gene delivery vehicles for in utero therapy [127–132].

Importantly, although MSC from each of these tissues appear similar with respect to phenotype and overall differentiative potential, studies at the RNA and protein level have now revealed that subtle differences exist between MSC from these various tissues, with MSC from each tissue possessing a molecular fingerprint indicative of their tissue of origin [121,122,133–137]. Using the fetal sheep model, we showed that these differences result in a bias for human MSC to home to and give rise to cells of their tissue of origin in vivo [138,139], suggesting that utilizing the appropriate source of MSC may make it possible to tailor the site(s) of engraftment. We and others have devoted a great deal of energy to demonstrating the ability of MSC from various sources to serve as therapeutics for liver disease [139–169]. It is now clear that, not only do MSC have the ability to generate, in vitro and in vivo, cells which are indistinguishable from native hepatocytes, but transplantation of MSC in a range of model systems can result in fairly robust formation of hepatocytes which repair a variety of inborn genetic defects, toxin induced injuries, and even fibrosis. The fetal sheep model provides a unique system in which to explore the full differentiative potential of various stem cell populations, since the continuous need for new cells within all of the organs during fetal development provides a permissive milieu in which gene-modified donor cells can engraft, proliferate, and differentiate. Furthermore, by performing the transplant at a stage in gestation when the fetus is considered to be largely immuno-naïve, it is possible to engraft human cells at significant levels, which persist for the lifespan of the animal due to induction of donor-specific tolerance [144–146]. Indeed, in ongoing studies, we have found that, after transplantation into fetal sheep, human MSC engraft at levels of up to 12% within the recipient liver [140,145,146,170–175], and contribute to both the parenchyma and the perivascular zones of the engrafted organs, placing them ideally for delivering FVIII into the circulation. Since FVIII levels of 3–5% of normal would convert a patient with severe hemophilia A to a moderate or mild phenotype, these levels of engraftment should be highly therapeutic. Given that the liver is thought to be the primary site of FVIII within the body, these collective results suggest that MSC may represent an ideal cell type for treating hemophilia A. However, although MSC engrafted at significant levels within organs that are natural sites of FVIII synthesis, only a small percent expressed endogenous FVIII, suggesting that simply transplanting “healthy” MSC will not likely provide an effective means of treating hemophilia A. By using gene therapy to engineer MSC to express FVIII, however, it is highly probable that the levels of engrafted MSC we have thus far achieved in utero could provide therapeutic benefit in hemophilia A. Unlike hematopoietic stem cells which are difficult to efficiently modify with most viral vectors while preserving their in vivo potential, MSC can be readily transduced with all of the major clinically prevalent viral vector systems including those based upon adenovirus [177–179], the murine retroviruses [179–183], lentiviruses [183–188], and AAV [189,190], and efficiently produce a wide

range of cytoplasmic, membrane-bound, and secreted protein products. Furthermore, human MSC are stable in culture, do not undergo transformation, and do not form tumors in vivo (in contrast to murine MSC). By transducing the MSC in vitro, rather than injecting the vector directly, there is no risk of off-target transduction, and the vector being employed simply needs a strong constitutively active promoter to ensure that all cells derived from the transplanted MSC continue to express the FVIII transgene and mediate a therapeutic effect. Importantly, the only documented cases of retroviral-induced insertional mutagenesis have been observed following genetic modification of hematopoietic stem cells [191–193]. There is no evidence that MSC transform or progress to clonal dominance following transduction, and recent studies have shown that even if genomic instability is intentionally induced, MSC undergo terminal differentiation rather than transformation [194]. Critical proof-of-principle studies have already shown that MSC can be transduced with FVIII-expressing viral vectors and secrete high levels of FVIII protein. FVIII purified from the conditioned medium of the transduced MSC was proven to have a specific activity, relative electrophoretic mobility, and proteolytic activation pattern that was virtually identical to that of FVIII produced by other commercial cell lines [195]. Given the widespread distribution and engraftment of MSC following their systemic infusion, the ability of MSC to give rise, in vivo, to cells of numerous tissue types, and their ability to efficiently process and secrete high amounts of biologically active FVIII, they are, not surprisingly, being viewed as ideal vehicles for delivering a FVIII transgene throughout the body and thus providing long-term/ permanent correction of hemophilia A [195–197]. In addition to their widespread engraftment and their ability to serve as delivery vehicles for the FVIII gene, the rather unique immunological properties of MSC may further increase their utility for treating hemophilia A. MSC do not normally express MHC class II or the co stimulatory molecules CD80 and CD82, unless they are stimulated with IFN- γ , and are thus known to be relatively hypo-immunogenic. As such, they do not provoke the proliferation of allogeneic lymphocytes or serve as very effective targets for lysis by cytotoxic T cells or NK cells. In fact, a large body of evidence is now accumulating that MSC can be readily transplanted across allogeneic barriers without eliciting an immune response [198,199]. Thus, if one wished to use MSC to treat hemophilia A, off-the-shelf MSC from an unrelated donor could theoretically be used, greatly increasing the feasibility of obtaining and using these stem cells for therapy. This property may also be important in the context of in utero therapies, given recent studies by Mackenzie and Flake showing that, while the fetal immune system has been presumed to still be largely naïve at the time of in utero transplant, both the fetal and the maternal immune system appear, at least within the mouse, to have the ability to negatively impact upon the engraftment of allogeneic cells [200,201]. Perhaps even more important from the standpoint of their potential use as hemophilia A therapeutics, more recent studies have provided evidence that MSC also appear to have the ability to exert both immunosuppressive and anti-inflammatory properties both in vitro and in vivo. These properties appear to result from MSC's ability to intervene, at multiple levels, with the generation and propagation of an immune response. To name just a few examples, MSC have been demonstrated to interfere with the generation and maturation of cytotoxic and helper T cells [202–211], dendritic cells [212–215], and B cells [216]. In addition to actively shutting down the generation of immune effector cells, MSC also have the ability to induce the formation of potent Tregs [118,217–219]. MSC are also known to express an arsenal of factors [118,205–207,217,220–224] that reduce local inflammation, blunt immune response, and counteract the chemotactic signals released to recruit immune cells to the site of injury/inflammation. It is thus tempting to speculate that these immune-dampening properties could enable the delivery of FVIII without eliciting an immune response and subsequent inhibitor formation, thus overcoming one of the major hurdles to plague current treatment/management of hemophilia A.

As will be discussed in the next section, however, our postnatal studies in the hemophilic sheep suggest that further work will be required to discover how to obtain these potential

immune benefits in the context of the ongoing injury/inflammation present in animals/patients with clinically advanced hemophilia A.

In addition to the aforementioned properties, preclinical animal studies examining the potential of MSC isolated from adult tissues have also highlighted another interesting and clinically valuable characteristic of MSC; their ability to selectively navigate to sites of injury and/or inflammation within the body. Once reaching these specific sites, the MSC then mediate repair both by engrafting and generating tissue-specific cells within the injured tissue [225–227], and by releasing trophic factors that blunt the inflammatory response and often promote healing by activating the tissue's own endogenous repair mechanisms. While the mechanisms responsible for this trafficking to sites of injury are currently not well understood, this observation raises the exciting possibility that, following systemic infusion, FVIII-expressing MSC could efficiently migrate to sites of active bleeding/ injury, thereby focusing the therapy where it is most needed. As will be discussed in the next section, our postnatal studies in the Hemophilia C sheep support this conclusion.

Need for Postnatal Strategies and Success with Novel Treatment

Despite the multiple advantages of early intervention, roughly 16,000 people within the US are already living with hemophilia A, and could thus not benefit from an in utero therapy. In addition, over 25% of hemophilia A-causing mutations arise *de novo* with no family history, making it unlikely this patient population would be screened prenatally. Even when diagnosis is made prenatally, the minimal risks and/or ethical issues associated with in utero therapy may be unacceptable to the parents. As such, the ability to treat postnatally is indispensable for a universal approach that could be applied to and benefit all hemophilia A patients. For this reason, we have begun exploring whether it is still possible to exploit the many advantages of MSC as a cellular vehicle for delivering a FVIII gene if these FVIII-expressing MSC are transplanted during early childhood, rather than in utero. To directly address this question, we recently tested a novel, non-ablative transplant based gene therapy in 2 pediatric hemophilia A lambs. During the first 3–5 months of life, both these animals had received frequent, on-demand infusions of human FVIII for multiple hematomas and chronic, progressive, debilitating hemarthroses of the leg joints which had resulted in severe defects in posture and gait, rendering them nearly immobile. In an ideal situation, one would use autologous cells to deliver a FVIII transgene, and thus avoid any complications due to MHC-mismatching. Unfortunately, the severe life-threatening phenotype of the hemophilia A sheep prevented us from collecting bone marrow aspirates to isolate autologous cells. We therefore elected to utilize haploidentical allogeneic cells from the ram that had sired the two hemophiliac lambs, hoping that, by using paternal (haploidentical) MSC, immunologic incompatibility between the donor and recipient should be minimized sufficiently to allow engraftment. Based on our prior work in the fetal sheep model, we knew that the intraperitoneal (IP) transplantation of MSC results in widespread engraftment throughout all of the major organs [140,145,174,228–230] and durable expression of vector-encoded genes [229–231], at least in the context of the developing fetus. We further reasoned that using the IP route would also have the advantage of enabling the cells to enter the circulation in an almost time-release fashion, after being engulfed by the omentum and absorbed through the peritoneal lymphatics. Importantly, the IP route also avoids the lung-trapping which hinders the efficient trafficking of MSC to desired target organs following IV administration, and also poses clinical risks due to emboli formation [232,233].

Following isolation, MSC were simultaneously transduced with 2 HIV-based lentivectors, the first of which encoded an expression/ secretion optimized porcine FVIII (pFVIII) transgene [234]. A porcine FVIII transgene was selected for two reasons. First, we had not yet cloned the ovine FVIII cDNA and constructed a B domain-deleted cassette that would fit

in a lentivector. Secondly, the pFVIII transgene had previously been shown to be expressed in/secreted from human cells at 10–100 times higher levels than human FVIII [8,9,235]. We reasoned that, with these very high levels of expression/secretion, even very low levels of engraftment of the transduced MSC might still be able to exert a therapeutic benefit. The second lentivector encoded an eGFP marker gene to facilitate tracking and identification of donor cells *in vivo*. Combining the 2 vectors in the same transduction unexpectedly resulted in preferential transduction with the eGFP vector, such that only about 15% of the MSC were transduced with the pFVIII-encoding vector, as assessed by qPCR. Once the transduced MSC had been sufficiently expanded, the first animal to be transplanted was treated with a dose of hFVIII calculated to correct the levels to 200%, to ensure no procedure-related bleeding occurred. The animal was then sedated, and 30×10^6 transduced MSC were transplanted into the peritoneal cavity under ultrasound guidance in the absence of any preconditioning. Following transplantation, FVIII activity (assessed by chromogenic assay) was undetectable in the circulation, but this animal's clinical picture improved dramatically. All spontaneous bleeding events ceased, and he enjoyed an event-free clinical course, devoid of spontaneous bleeds, obviating the need for hFVIII infusions. Existing hemarthroses resolved, the animal's joints recovered fully and resumed normal appearance (as assessed by two attending veterinarians), and he regained normal posture and gait, resuming a normal activity level. To our knowledge, this represents the first report of phenotypic correction of severe hemophilia A in large animal model following transplantation of cells engineered to produce FVIII, and the first time that reversal of chronic debilitating hemarthroses has been achieved.

Based on the remarkable clinical improvement we had achieved in this first animal, we transplanted a second animal with 120×10^6 paternal MSC which had been subjected to 2 additional rounds of transduction with the pFVIII vector, such that > 95% of these cells were transduced and expressing pFVIII. We anticipated that by transplanting 4x's the number of cells with roughly 6x's the transduction efficiency, we would achieve pronounced improvement and therapeutic levels of FVIII in the circulation of this animal, given that the transplanted cells were producing ~24x's the levels of FVIII (720units/24hrs) as those transplanted into the first animal. In similarity to the first animal, hemarthroses present in this second animal at the time of transplant resolved, and he resumed normal activity shortly after transplantation. This second animal also became factor-independent following the transplant. These results thus confirm the ability of this MSC-based approach to provide phenotypic correction in this large animal model of hemophilia A. However, just as we had observed in the first animal, no FVIII was detectable in the circulation of this animal, making the mechanism by which this procedure produced such pronounced clinical improvement indeterminate.

Despite the pronounced clinical improvement we observed in the first animal, he mounted a rapid and fairly robust immune response to FVIII, in similarity to prior studies performed with hemophilia A mice [235]. Before transplant, this first animal had Bethesda titers against hFVIII of only ~3, yet this lifesaving procedure resulted in a rise in Bethesda titer to ~800 against the vector-encoded pFVIII and nearly 700 to hFVIII. The formation of such high titer inhibitors with cross-reactivity to the human protein was surprising, given the well established ability to successfully use porcine FVIII products in human patients to bypass existing anti-hFVIII inhibitors [236–239]. Similarly, despite having no detectable inhibitors prior to transplant, the second animal receiving the higher FVIII-expressing cell dose developed titers of ~150 Bethesda units against the vector-encoded pFVIII following transplantation which also exhibited cross-reactivity to the human protein. Following euthanasia of these animals, we performed a detailed tissue analysis of to begin deciphering the mechanism whereby this novel MSC-based gene delivery produced its pronounced therapeutic effect at a systemic level. PCR analysis demonstrated readily detectable levels of

MSC engraftment in nearly all tissues analyzed, including liver, lymph nodes, intestine, lung, kidney, omentum, and thymus. These molecular analyses thereby proved our hypothesis that it is possible to achieve widespread durable engraftment of MSC following transplantation in a postnatal setting in a large animal model without the need for preconditioning/ablation, and in the absence of any selective advantage for the donor cells. Confocal immunofluorescence analysis on frozen tissue sections revealed large numbers of FVIII-expressing MSC within the synovium of the joints which exhibited hemarthrosis at the time of transplant, suggesting the transplanted MSC possessed the intrinsic ability to home to and persist within sites of ongoing injury/inflammation, releasing FVIII locally within the joint, providing an explanation for the dramatic improvement we observed in this animal's joints. This finding is in agreement with prior studies [240], showing that local delivery of FIX-AAV to the joints of mice with injury-induced hemarthroses led to resolution of the hemarthroses in the absence of any detectable FIX in the circulation. While this finding provides an explanation for the reversal of the joint pathology present in these animals at transplant, it cannot explain the observed systemic benefits such as the cessation of spontaneous bleeding events.

Thus far, confocal analysis has also revealed engrafted cells within the small intestine, demonstrating that MSC can still engraft within the intestine following postnatal transplantation, just as we had observed in our prior studies in fetal recipients [229]. Given the ease with which proteins secreted from cells within the intestine can enter the circulation, future studies aimed at improving the levels of engraftment within the intestine have the potential to greatly improve the systemic release of FVIII. In addition to the intestine and hemarthrotic joints, significant levels of engraftment were also seen within the thymus of this animal. While the ability of the transplanted MSC to traffic to the thymus could clearly have important implications for the likelihood of long-term correction with this approach to hemophilia A treatment, additional studies are required to determine with which cells within the thymus these MSC are interacting to ascertain the immunologic ramifications of thymic engraftment.

Conclusions

Current hemophilia A treatments allow many patients with hemophilia to live relatively normal lives, but their high cost, the need for lifelong therapy, and the inaccessibility of these therapies to the vast majority of patients with hemophilia A worldwide [5] highlight the need to develop novel therapies offering longer-lasting benefit or permanent cure [7,8,10–14]. Based on their developmental similarities to humans, we have employed sheep as a model system to study the potential of in utero gene therapy and in utero MSC transplantation to correct a disease like hemophilia A prior to birth, and have shown that direct vector injection results in levels of gene transfer that would likely be therapeutic in hemophilia A and induces durable immune tolerance to the vector-encoded genes, but possesses the inherent risk of off-target transduction.

Similarly, the transplantation of MSC in utero led to significant levels of widespread cell engraftment in both the parenchyma and the perivascular regions of multiple tissues, placing the cells ideally for release of FVIII into the circulation. Unfortunately, expression of the endogenous FVIII gene by these cells following engraftment and differentiation was too low to be of therapeutic value. It thus appears that a combination of these two approaches may represent the ideal means of treating hemophilia A prior to birth. Having recently re-established a line of sheep that accurately recapitulates both the genetics and the clinical symptoms of the severe form of human hemophilia A, we are now ideally poised to address this issue. In similarity to human patients, this line of sheep exhibits a severe bleeding phenotype with frequent spontaneous hemarthroses leading to reduced locomotion, muscular

hematomas, and episodes of hematuria and internal bleeding leading to death. The nature of the mutation found in these animals further adds to the uniqueness of this model. Murine models have been generated through knockout/deletion technology, and the naturally occurring dog colonies exhibit gene inversions [241]. In similarity to mutations seen in many human patients [38], hemophilia A in sheep is caused by a premature stop codon with a frame shift mutation, making this sheep colony the first large animal model yet described to possess a mutation of this kind. It is our hope that the availability of this animal model that closely parallels normal human weight and physiology, and in which the severity and symptoms of the disease clearly resemble that of humans, will provide researchers in the field with a valuable preclinical resource for developing novel therapies, such as those utilizing stem cell transplantation and gene therapy, for hemophilia A. In recent studies, we used this line of sheep to test a novel postnatal approach to treating hemophilia A in which MSC served as delivery vehicles for a pFVIII transgene. This approach was technically straightforward, involving a single injection into the peritoneal cavity under ultrasound guidance, in the absence of any prior cytoablation/conditioning, and thus posed minimal risk to the recipient. This MSC-based approach converted both animals treated to-date from a severe, life-threatening phenotype to a moderate phenotype, devoid of spontaneous bleeds, but still bleeding in response to accidental trauma. Remarkably, this approach also resulted in a complete reversal of the joint stiffness/swelling as well as the gait and postural defects that had developed as a result of frequent hemarthroses during the first months of life.

To our knowledge, this represents the first time that reversal of the severe, crippling hemarthroses which plague human patients with hemophilia A has been achieved. These results thus open the door to the development of new MSC-based therapies for this debilitating condition, either systemically or, perhaps, administered directly into affected joints of hemophilia patients. Despite the marked clinical success we achieved, however, both animals developed high-titer inhibitors, likely limiting both the magnitude and duration of the therapeutic effect. Mechanistic studies are currently underway to understand and ultimately overcome the formation of inhibitors resultant from this procedure since, in their absence, this approach could result in even more pronounced clinical improvement. It is important to note that, were this same procedure implemented in utero, the possibility of inhibitor formation would be eliminated, possibly making this approach to hemophilia A treatment curative.

Acknowledgments

This work was supported by NIH grant R01 HL073737.

References

1. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. *N Engl J Med*. 2001; 344:1773–1779. [PubMed: 11396445]
2. Agaliotis D Hemophilia (2006) Overview.
3. High KA. Gene transfer as an approach to treating hemophilia. *Semin Thromb Hemost*. 2003; 29:107–120. [PubMed: 12640573]
4. Kay MA, High K. Gene therapy for the hemophilias. *Proc Natl Acad Sci U S A*. 1999; 96:9973–9975. [PubMed: 10468539]
5. Kaveri SV, Dasgupta S, Andre S, Navarrete AM, Repessé Y, et al. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. *Haemophilia*. 2007; 13(Suppl 5):61–64. [PubMed: 18078399]
6. High KA. Gene therapy for haemophilia: a long and winding road. *J Thromb Haemost*. 2011; 9(Suppl 1):2–11. [PubMed: 21781236]

7. Arruda VR. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models. *J Thromb Haemost.* 2006; 4:1215–1217. [PubMed: 16706962]
8. Doering CB, Denning G, Dooriss K, Gangadharan B, Johnston JM, et al. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. *Mol Ther.* 2009; 17:1145–1154. [PubMed: 19259064]
9. Doering CB, Gangadharan B, Dukart HZ, Spencer HT. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity. *Mol Ther.* 2007; 15:1093–1099. [PubMed: 17387335]
10. Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. *Blood.* 2007; 110:2855–2863. [PubMed: 17569821]
11. Lipshutz GS, Sarkar R, Flebbe-Rehwaltd L, Kazazian H, Gaensler KM. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. *Proc Natl Acad Sci U S A.* 1999; 96:13324–13329. [PubMed: 10557319]
12. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency. *ILAR J.* 2009; 50:144–167. [PubMed: 19293459]
13. Ponder KP. Gene therapy for hemophilia. *Curr Opin Hematol.* 2006; 13:301–307. [PubMed: 16888433]
14. Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. *Blood.* 2008; 112:2713–2721. [PubMed: 18495954]
15. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, et al. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. *Thromb Haemost.* 1997; 77:591–599. [PubMed: 9066015]
16. Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. *Thromb Haemost.* 2002; 87:659–665. [PubMed: 12008949]
17. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, et al. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. *Proc Natl Acad Sci U S A.* 2002; 99:12991–12996. [PubMed: 12242334]
18. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. *Nat Genet.* 1995; 10:119–121. [PubMed: 7647782]
19. Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophilic mice. *Hum Gene Ther.* 1999; 10:1791–1802. [PubMed: 10446919]
20. García-Martín C, Chuah MK, Van Damme A, Robinson KE, Vanzielegheem B, et al. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. *J Gene Med.* 2002; 4:215–223. [PubMed: 11933222]
21. Moayeri M, Hawley TS, Hawley RG. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. *Mol Ther.* 2005; 12:1034–1042. [PubMed: 16226058]
22. Moayeri M, Ramezani A, Morgan RA, Hawley TS, Hawley RG. Sustained phenotypic correction of hemophilia A mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. *Mol Ther.* 2004; 10:892–902. [PubMed: 15509507]
23. Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. *Mol Ther.* 2002; 5:63–73. [PubMed: 11786047]
24. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. *Blood.* 2004; 103:1253–1260. [PubMed: 14551134]

25. Ide LM, Iwakoshi NN, Gangadharan B, Jobe S, Moot R, et al. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. *J Gene Med.* 2010; 12:333–344. [PubMed: 20209485]
26. Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. *Blood.* 2001; 97:107–113. [PubMed: 11133749]
27. Scallan CD, Lillicrap D, Jiang H, Qian X, Patarroyo-White SL, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. *Blood.* 2003; 102:2031–2037. [PubMed: 12738670]
28. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med.* 2011; 365:2357–2365. [PubMed: 22149959]
29. Neuenschwander S, Kissling-Albrecht L, Heiniger J, Backfisch W, Stranzinger G, et al. Inherited defect of blood clotting factor VIII (haemophilia A) in sheep. *Thromb Haemost.* 1992; 68:618–620. [PubMed: 1455410]
30. Backfisch W, Neuenschwander S, Giger U, Stranzinger G, Pliska V. Carrier detection of ovine hemophilia A using an RFLP marker, and mapping of the factor VIII gene on the ovine X-chromosome. *J Hered.* 1994; 85:474–478. [PubMed: 7995928]
31. Neuenschwander S, Pliska V. Factor VIII in blood plasma of haemophilic sheep: analysis of clotting time-plasma dilution curves. *Haemostasis.* 1994; 24:27–35. [PubMed: 7959353]
32. Porada CD, Sanada C, Long CR, Wood JA, Desai J, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. *J Thromb Haemost.* 2010; 8:276–285. [PubMed: 19943872]
33. Almeida-Porada G, Desai J, Long C, Westhusin M, Pliska V, et al. Re-establishment and characterization of an extinct line of sheep with a spontaneous bleeding disorder that closely recapitulates human hemophilia A. *Blood.* 2007; 110:347a.
34. Sanada C, Wood JA, Liu W, Lozier JN, Almeida-Porada G, et al. A Frame Shift-Induced Stop Codon Causes Hemophilia A in Sheep. *Blood.* 2008; 112:Abstract #3378.
35. Porada CD, Sanada C, Long CR, Wood JA, Desai J, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. *J Thromb Haemost.* 2010; 8:276–285. [PubMed: 19943872]
36. Porada CD, Sanada C, Long CR, Wood JA, Desai J, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. *J Thromb Haemost.* 2010; 8:276–285. [PubMed: 19943872]
37. Porada CD, Sanada C, Long CR, Wood JA, Desai J, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. *J Thromb Haemost.* 2010; 8:276–285. [PubMed: 19943872]
38. Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. A novel mutation (2409delT) in exon 14 of the factor VIII gene causes severe haemophilia A. *Hum Hered.* 2000; 50:266–267. [PubMed: 10782022]
39. High K. Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients? *J Thromb Haemost.* 2005; 3:1682–1691. [PubMed: 16102034]
40. Maddox JF, Mackay CR, Brandon MR. Ontogeny of ovine lymphocytes. I. An immunohistological study on the development of T lymphocytes in the sheep embryo and fetal thymus. *Immunology.* 1987; 62:97–105. [PubMed: 3308692]
41. Maddox JF, Mackay CR, Brandon MR. Ontogeny of ovine lymphocytes. III. An immunohistological study on the development of T lymphocytes in sheep fetal lymph nodes. *Immunology.* 1987; 62:113–118. [PubMed: 3308690]
42. Maddox JF, Mackay CR, Brandon MR. Ontogeny of ovine lymphocytes. II. An immunohistological study on the development of T lymphocytes in the sheep fetal spleen. *Immunology.* 1987; 62:107–112. [PubMed: 3308689]

43. Osburn BI. The ontogeny of the ruminant immune system and its significance in the understanding of maternal-fetal-neonatal relationships. *Adv Exp Med Biol.* 1981; 137:91–103. [PubMed: 6277167]
44. Sawyer M, Moe J, Osburn BI. Ontogeny of immunity and leukocytes in the ovine fetus and elevation of immunoglobulins related to congenital infection. *Am J Vet Res.* 1978; 39:643–648. [PubMed: 646200]
45. Silverstein AM, Parshall CJ Jr, Uhr JW. Immunologic maturation in utero: kinetics of the primary antibody response in the fetal lamb. *Science.* 1966; 154:1675–1677. [PubMed: 5924202]
46. Tuboly S, Glávits R, Bucsek M. Stages in the development of the ovine immune system. *Zentralbl Veterinarmed B.* 1984; 31:81–95. [PubMed: 6720170]
47. McCarroll DR, Waters DC, Steidley KR, Clift R, McDonald TP. Canine platelet von Willebrand factor: quantification and multimeric analysis. *Exp Hematol.* 1988; 16:929–937. [PubMed: 3263280]
48. Parker MT, Turrentine MA, Johnson GS. von Willebrand factor in lysates of washed canine platelets. *Am J Vet Res.* 1991; 52:119–125. [PubMed: 2021239]
49. Montgomery RR, Shi Q. Platelet and endothelial expression of clotting factors for the treatment of hemophilia. *Thromb Res.* 2012; 129(Suppl 2):S46–48. [PubMed: 22421106]
50. Shi Q, Montgomery RR. Platelets as delivery systems for disease treatments. *Adv Drug Deliv Rev.* 2010; 62:1196–1203. [PubMed: 20619307]
51. Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. *J Clin Invest.* 2006; 116:1974–1982. [PubMed: 16823491]
52. Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. *Blood.* 1999; 94:2179–2191. [PubMed: 10498587]
53. Troeger C, Surbek D, Schöberlein A, Schatt S, Dudler L, et al. In utero haematopoietic stem cell transplantation. Experiences in mice, sheep and humans. *Swiss Med Wkly.* 2006; 136:498–503. [PubMed: 16947088]
54. Muench MO, Bárcena A. Stem cell transplantation in the fetus. *Cancer Control.* 2004; 11:105–118. [PubMed: 15024347]
55. Tiblad E, Westgren M. Fetal stem-cell transplantation. *Best Pract Res Clin Obstet Gynaecol.* 2008; 22:189–201. [PubMed: 18035592]
56. Flake AW, Roncarolo MG, Puck JM, Almeida-Porada G, Evans MI, et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. *N Engl J Med.* 1996; 335:1806–1810. [PubMed: 8943162]
57. Merianos D, Heaton T, Flake AW. In utero hematopoietic stem cell transplantation: progress toward clinical application. *Biol Blood Marrow Transplant.* 2008; 14:729–740. [PubMed: 18541191]
58. Roybal JL, Santore MT, Flake AW. Stem cell and genetic therapies for the fetus. *Semin Fetal Neonatal Med.* 2010; 15:46–51. [PubMed: 19540822]
59. Tabor A, Alfievic Z. Update on procedure-related risks for prenatal diagnosis techniques. *Fetal Diagn Ther.* 2010; 27:1–7. [PubMed: 20051662]
60. Klein I, Andrikovics H, Bors A, Nemes L, Tordai A, et al. A haemophilia A and B molecular genetic diagnostic programme in Hungary: a highly informative and cost-effective strategy. *Haemophilia.* 2001; 7:306–312. [PubMed: 11380636]
61. Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. *Semin Thromb Hemost.* 2005; 31:544–554. [PubMed: 16276463]
62. Sasanakul W, Chuansumrit A, Ajjimakorn S, Krasaesub S, Sirachainan N, et al. Cost-effectiveness in establishing hemophilia carrier detection and prenatal diagnosis services in a developing country with limited health resources. *Southeast Asian J Trop Med Public Health.* 2003; 34:891–898. [PubMed: 15115107]
63. Porada CD, Park P, Almeida-Porada G, Zanjani ED. The sheep model of in utero gene therapy. *Fetal Diagn Ther.* 2004; 19:23–30. [PubMed: 14646413]

64. Porada GA, Porada C, Zanjani ED. The fetal sheep: a unique model system for assessing the full differentiative potential of human stem cells. *Yonsei Med J.* 2004; 45(Suppl):7–14. [PubMed: 15250043]
65. Shaw SW, Bollini S, Nader KA, Gastadello A, Mehta V, et al. Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. *Cell Transplant.* 2011; 20:1015–1031. [PubMed: 21092404]
66. Hollestelle MJ, Thinnies T, Crain K, Stiko A, Kruijt JK, et al. Tissue distribution of factor VIII gene expression in vivo—a closer look. *Thromb Haemost.* 2001; 86:855–861. [PubMed: 11583319]
67. Fausto; Naw, EM. *The Liver: Biology and Pathobiology.* Arias, AM.; Boyer, JL.; Fausto, N.; Jacoby, WB.; Scachter, D.; Shafritz, DA., editors. New York: Raven; 1994. p. 1059–1084.
68. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. *Science.* 1993; 262:117–119. [PubMed: 8211118]
69. BILLINGHAM RE, BRENT L, MEDAWAR PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. *Proc R Soc Lond B Biol Sci.* 1954; 143:58–80. [PubMed: 13224651]
70. Park PZE, Porada CD. Risks to the germline following in utero gene transfer. *Molecular Therapy.* 2003; 7:S137.
71. Park PJ, APG, Glimp HA, Zanjani ED, Porada CD. Germline cells may be at risk following direct injection gene therapy in utero. *Blood.* 2003; 102:874a.
72. Park PJ, Tellez J, Almeida-Porada G, Zanjani ED, Porada CD. Male germline cells appear to be at risk following direct injection gene transfer in utero. *Molecular Therapy.* 2004; 9:S403.
73. Porada CD, A-PMG, Torabi A, Zanjani ED. In utero transduction of hematopoietic cells is enhanced at early gestational ages. *Blood.* 2001; 98:214a.
74. Porada CD, A-PMG, Park P, Zanjani ED. In utero transduction of lung and liver: gestational age determines gene transfer efficiency. *Blood.* 2001; 98:215a.
75. Porada, CD.; PP; Torabi, A.; Almeida-Porada, G.; Zanjani, ED. Gestational age determines gene transfer efficiency to hematopoietic cells, lung and liver following in utero retroviral-mediated gene transfer. *Molecular Therapy, American Society of Gene Therapy, Annual Meeting; Boston, MA.* 2002.
76. Porada CD, Park PJ, Almeida-Porada G, Liu W, Ozturk F, et al. Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer. *Mol Ther.* 2005; 11:284–293. [PubMed: 15668140]
77. Porada CD, Park PJ, Tellez J, Ozturk F, Glimp HA, et al. Male germ-line cells are at risk following direct-injection retroviral-mediated gene transfer in utero. *Mol Ther.* 2005; 12:754–762. [PubMed: 16084775]
78. Porada CD, Tran N, Eglitis M, Moen RC, Troutman L, et al. In utero gene therapy: transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. *Hum Gene Ther.* 1998; 9:1571–1585. [PubMed: 9694156]
79. Tran ND, Porada CD, Zhao Y, Almeida-Porada G, Anderson WF, et al. In utero transfer and expression of exogenous genes in sheep. *Exp Hematol.* 2000; 28:17–30. [PubMed: 10658673]
80. Porada, CD.; PP; Torabi, A.; Almeida-Porada, G.; Zanjani, ED. Gestational age determines gene transfer efficiency to hematopoietic cells, lung and liver following in utero retroviral-mediated gene transfer. *Molecular Therapy, American Society of Gene Therapy, Annual Meeting; Boston, MA.* 2002.
81. Porada CD, Harrison-Findik DD, Sanada C, Valiente V, Thain D, et al. Development and characterization of a novel CD34 monoclonal antibody that identifies sheep hematopoietic stem/progenitor cells. *Exp Hematol.* 2008; 36:1739–1749. [PubMed: 19007686]
82. Porada CD, A-PMG, Park P, Zanjani ED. In utero transduction of lung and liver: gestational age determines gene transfer efficiency. *Blood.* 2001; 98:215a.
83. Chen XG, Zhu HZ, Gong JL, Li F, Xue JL. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero. *Acta Pharmacol Sin.* 2004; 25:789–793. [PubMed: 15169633]

84. David A, Cook T, Waddington S, Peebles D, Nivsarkar M, et al. Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero. *Hum Gene Ther.* 2003; 14:353–364. [PubMed: 12659676]
85. Jimenez DF, Lee CI, O'Shea CE, Kohn DB, Tarantal AF. HIV-1-derived lentiviral vectors and fetal route of administration on transgene biodistribution and expression in rhesus monkeys. *Gene Ther.* 2005; 12:821–830. [PubMed: 15815706]
86. Lee CC, Jimenez DF, Kohn DB, Tarantal AF. Fetal gene transfer using lentiviral vectors and the potential for germ cell transduction in rhesus monkeys (*Macaca mulatta*). *Hum Gene Ther.* 2005; 16:417–425. [PubMed: 15871673]
87. Park PJ, Colletti E, Ozturk F, Wood JA, Tellez J, et al. Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep. *Hum Gene Ther.* 2009; 20:201–215. [PubMed: 19301473]
88. Porada CD, Tran ND, Almeida-Porada G, Glimp HA, Pixley JS, et al. Transduction of long-term-engrafting human hematopoietic stem cells by retroviral vectors. *Hum Gene Ther.* 2002; 13:867–879. [PubMed: 11975852]
89. Tarantal AF, Han VK, Cochrum KC, Mok A, daSilva M, et al. Fetal rhesus monkey model of obstructive renal dysplasia. *Kidney Int.* 2001; 59:446–456. [PubMed: 11168926]
90. Tarantal AF, Lee CC. Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (*Macaca mulatta*). *Hum Gene Ther.* 2010; 21:143–148. [PubMed: 19751148]
91. Tarantal AF, Lee CC, Jimenez DF, Cherry SR. Fetal gene transfer using lentiviral vectors: in vivo detection of gene expression by microPET and optical imaging in fetal and infant monkeys. *Hum Gene Ther.* 2006; 17:1254–1261. [PubMed: 17134373]
92. Tarantal AF, Lee CI, Ekert JE, McDonald R, Kohn DB, et al. Lentiviral vector gene transfer into fetal rhesus monkeys (*Macaca mulatta*): lung-targeting approaches. *Mol Ther.* 2001; 4:614–621. [PubMed: 11735346]
93. Tarantal AF, McDonald RJ, Jimenez DF, Lee CC, O'Shea CE, et al. Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (*Macaca mulatta*): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. *Mol Ther.* 2005; 12:87–98. [PubMed: 15963924]
94. Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, et al. Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems. *Mol Ther.* 2001; 3:128–138. [PubMed: 11237669]
95. Themis M, Schneider H, Kiserud T, Cook T, Adebakin S, et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. *Gene Ther.* 1999; 6:1239–1248. [PubMed: 10455432]
96. Waddington SN, Buckley SM, Nivsarkar M, Jezzard S, Schneider H, et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. *Blood.* 2003; 101:1359–1366. [PubMed: 12393743]
97. Waddington SN, Nivsarkar MS, Mistry AR, Buckley SM, Kembell-Cook G, et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. *Blood.* 2004; 104:2714–2721. [PubMed: 15231566]
98. Lipshutz GS, Flebbe-Rehwaltd L, Gaensler KM. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration. *Mol Ther.* 2000; 2:374–380. [PubMed: 11020353]
99. Schneider H, Adebakin S, Themis M, Cook T, Douar AM, et al. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. *J Gene Med.* 1999; 1:424–432. [PubMed: 10753068]
100. Schneider H, Mühle C, Douar AM, Waddington S, Jiang QJ, et al. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero. *J Gene Med.* 2002; 4:46–53. [PubMed: 11828387]

101. Tran ND, Porada CD, Almeida-Porada G, Glimp HA, Anderson WF, et al. Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. *Blood*. 2001; 97:3417–3423. [PubMed: 11369632]
102. David AL, McIntosh J, Peebles DM, Cook T, Waddington S, et al. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep. *Hum Gene Ther*. 2011; 22:419–426. [PubMed: 20919876]
103. Mattar CN, Nathwani AC, Waddington SN, Dighe N, Kaeppl C, et al. Stable human FIX expression after 0.9G intrauterine gene transfer of selfcomplementary adeno-associated viral vector 5 and 8 in macaques. *Mol Ther*. 2011; 19:1950–1960. [PubMed: 21629224]
104. Ponder KP. Hemophilia gene therapy: a Holy Grail found. *Mol Ther*. 2011; 19:427–428. [PubMed: 21358702]
105. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997– 2006). *Haemophilia*. 2009; 15:1027–1031. [PubMed: 19515028]
106. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. *Lancet*. 1992; 339:594–598. [PubMed: 1347102]
107. Doeber J, Breindl M, Willecke K, Jaenisch R. Genetic transmission of Moloney leukemia virus: mapping of the chromosomal integration site. *Haematol Blood Transfus*. 1979; 23:561–568. [PubMed: 544367]
108. Jaenisch R. Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. *Proc Natl Acad Sci U S A*. 1976; 73:1260–1264. [PubMed: 1063407]
109. Jähner D, Haase K, Mulligan R, Jaenisch R. Insertion of the bacterial gpt gene into the germ line of mice by retroviral infection. *Proc Natl Acad Sci U S A*. 1985; 82:6927–6931. [PubMed: 2413448]
110. Soriano P, Jaenisch R. Retroviruses as probes for mammalian development: allocation of cells to the somatic and germ cell lineages. *Cell*. 1986; 46:19–29. [PubMed: 3013418]
111. Alloli N, Thomas JL, Chebloune Y, Nigon VM, Verdier G, et al. Use of retroviral vectors to introduce and express the beta-galactosidase marker gene in cultured chicken primordial germ cells. *Dev Biol*. 1994; 165:30–37. [PubMed: 8088448]
112. Park PJ, A-PG, Glimp HA, Zanjani ED, Porada CD. Germline cells may be at risk following direct injection gene therapy in utero. *Blood*. 2003; 102:874.
113. Kazazian HH Jr. An estimated frequency of endogenous insertional mutations in humans. *Nat Genet*. 1999; 22:130. [PubMed: 10369250]
114. Friedenstein AJ. Osteogenic stem cells in the bone marrow. *Journal of Bone and Mineral Research*. 1991; 7:243–272.
115. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation*. 1974; 17:331–340. [PubMed: 4150881]
116. Caplan AI. Mesenchymal stem cells. *J Orthop Res*. 1991; 9:641–650. [PubMed: 1870029]
117. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. *Exp Hematol*. 1999; 27:1460–1466. [PubMed: 10480437]
118. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. *Transpl Int*. 2009; 22:365–376. [PubMed: 19000235]
119. Almeida-Porada G, El Shabrawy D, Porada C, Zanjani ED. Differentiative potential of human metanephric mesenchymal cells. *Exp Hematol*. 2002; 30:1454– 1462. [PubMed: 12482508]
120. Fan CG, Tang FW, Zhang QJ, Lu SH, Liu HY, et al. Characterization and neural differentiation of fetal lung mesenchymal stem cells. *Cell Transplant*. 2005; 14:311–321. [PubMed: 16052912]
121. Götherström C, West A, Liden J, Uzunel M, Lahesmaa R, et al. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. *Haematologica*. 2005; 90:1017–1026. [PubMed: 16079100]
122. in 't Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit

- a similar immunophenotype but a heterogeneous multilineage differentiation potential. *Haematologica*. 2003; 88:845–852. [PubMed: 12935972]
123. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood*. 2004; 103:1669–1675. [PubMed: 14576065]
 124. Morizono K, De Ugarte DA, Zhu M, Zuk P, Elbarbary A, et al. Multilineage cells from adipose tissue as gene delivery vehicles. *Hum Gene Ther*. 2003; 14:59–66. [PubMed: 12573059]
 125. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JJ, et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell*. 2002; 13:4279–4295. [PubMed: 12475952]
 126. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001; 7:211–228. [PubMed: 11304456]
 127. Fernandes RA, Wenceslau CV, Reginato AL, Kerkis I, Miglino MA. Derivation and characterization of progenitor stem cells from canine allantois and amniotic fluids at the third trimester of gestation. *Placenta*. 2012
 128. Shaw SW, Bollini S, Nader KA, Gastadello A, Mehta V, et al. Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. *Cell Transplant*. 2011; 20:1015–1031. [PubMed: 21092404]
 129. Shaw SW, David AL, De Coppi P. Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid. *Curr Opin Obstet Gynecol*. 2011; 23:109–116. [PubMed: 21386681]
 130. Weber B, Emmert MY, Behr L, Schoenauer R, Brokopp C, et al. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. *Biomaterials*. 2012; 33:4031–4043. [PubMed: 22421386]
 131. Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, et al. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. *Clin Exp Immunol*. 2012; 167:543–555. [PubMed: 22288598]
 132. Poloni A, Maurizi G, Babini L, Serrani F, Berardinelli E, et al. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. *Cell Transplant*. 2011; 20:643–654. [PubMed: 21054927]
 133. Garol NJ, Yamagami T, Osborne C, Porada CD, Zanjani ED, et al. Tissue-specific molecular signature may explain differentiative bias of human MSC from different tissues. *Blood*. 2007; 110:570a.
 134. Mazhari S, Desai J, Chamberlain J, Porada C, Zanjani ED. Proteomic Analysis Reveals Intrinsic Differences between Phenotypically Identical Mesenchymal Stem Cells. *Blood*. 2005:106. [PubMed: 16174759]
 135. Mazhari SM, Porada CD, Chamberlain J, Zanjani ED, Almeida-Porada G. Characterization of membrane proteins of mesenchymal stem cells from human liver. *Experimental Hematology*. 2006; 34:80.
 136. Lee RH, Kim B, Choi I, Kim H, Choi HS, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. *Cell Physiol Biochem*. 2004; 14:311–324. [PubMed: 15319535]
 137. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells*. 2006; 24:1294–1301. [PubMed: 16410387]
 138. Chamberlain J, Frias A, Porada C, Zanjani ED, Almeida-Porada G, et al. Neural Generation in vivo differs with route of administration and source of mesenchymal stem cells. *Experimental Hematology*. 2005; 33:47a.
 139. Almeida-Porada MG, Chamberlain J, Frias A, Porada CD, Zanjani ED. Tissue of Origin Influences In Vivo Differentiative Potential of Mesenchymal Stem Cells. *Blood*. 2003; 102:abstract #1304.
 140. Chamberlain J, Yamagami T, Colletti E, Theise ND, Desai J, et al. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. *Hepatology*. 2007; 46:1935–1945. [PubMed: 17705296]
 141. Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, et al. In vitro hepatic differentiation of human mesenchymal stem cells. *Hepatology*. 2004; 40:1275–1284. [PubMed: 15562440]

142. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. *Blood*. 2005; 106:756–763. [PubMed: 15817682]
143. Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. *J Clin Invest*. 2002; 109:1291–1302. [PubMed: 12021244]
144. Almeida-Porada G, Porada C, Zanjani ED. Adult stem cell plasticity and methods of detection. *Rev Clin Exp Hematol*. 2001; 5:26–41. [PubMed: 11486730]
145. Almeida-Porada G, Porada C, Zanjani ED. Plasticity of human stem cells in the fetal sheep model of human stem cell transplantation. *Int J Hematol*. 2004; 79:1–6. [PubMed: 14979471]
146. Almeida-Porada G, Zanjani ED. A large animal noninjury model for study of human stem cell plasticity. *Blood Cells Mol Dis*. 2004; 32:77–81. [PubMed: 14757417]
147. Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. *Gut*. 2009; 58:570–581. [PubMed: 19022918]
148. Aurich I, Mueller LP, Aurich H, Luetzkendorf J, Tisljar K, et al. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. *Gut*. 2007; 56:405–415. [PubMed: 16928726]
149. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. *J Gastroenterol Hepatol*. 2008; 24:70–77. [PubMed: 18624899]
150. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. *Stem Cells*. 2008; 26:2705–2712. [PubMed: 18535155]
151. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. *Hepatology*. 2007; 46:219–228. [PubMed: 17596885]
152. Colletti EJ, Airey JA, Zanjani ED, Porada CD, Almeida-Porada G. Human Mesenchymal Stem Cells differentiate promptly into tissue-specific cell types without cell fusion, mitochondrial or membrane vesicular transfer in fetal sheep. *Blood*. 2007; 110:135a.
153. Colletti EJ, Airey JA, Liu W, Simmons PJ, Zanjani ED, et al. Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer. *Stem Cell Res*. 2009; 2:125–138. [PubMed: 19383418]
154. di Bonzo LV, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. *Gut*. 2008; 57:223–231. [PubMed: 17639088]
155. Enns GM, Millan MT. Cell-based therapies for metabolic liver disease. *Mol Genet Metab*. 2008; 95:3–10. [PubMed: 18640065]
156. Fang B, Shi M, Liao L, Yang S, Liu Y. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. *Transplantation*. 2004; 78:83–88. [PubMed: 15257043]
157. Higashiyama R, Inagaki Y, Hong YY, Kushida M, Nakao S, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. *Hepatology*. 2007; 45:213–222. [PubMed: 17187438]
158. Ishikawa T, Terai S, Urata Y, Marumoto Y, Aoyama K, et al. Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes. *Cell Tissue Res*. 2006; 323:221–231. [PubMed: 16228231]
159. Luk JM, Wang PP, Lee CK, Wang JH, Fan ST. Hepatic potential of bone marrow stromal cells: development of in vitro co-culture and intra-portal transplantation models. *J Immunol Methods*. 2005; 305:39–47. [PubMed: 16150456]
160. Lysy PA, Campard D, Smets F, Malaise J, Mourad M, et al. Persistence of a chimerical phenotype after hepatocyte differentiation of human bone marrow mesenchymal stem cells. *Cell Prolif*. 2008; 41:36–58. [PubMed: 18211285]

161. Muraca M, Ferraresso C, Vilei MT, Granato A, Quarta M, et al. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. *Gut*. 2007; 56:1725–1735. [PubMed: 17641081]
162. Oyagi S, Hirose M, Kojima M, Okuyama M, Kawase M, et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl₄-injured rats. *J Hepatol*. 2006; 44:742–748. [PubMed: 16469408]
163. Popp FC, Piso P, Schlitt HJ, Dahlke MH. Therapeutic potential of bone marrow stem cells for liver diseases. *Curr Stem Cell Res Ther*. 2006; 1:411–418. [PubMed: 18220884]
164. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T. Transplantation of bone marrow cells reduces CCl₄-induced liver fibrosis in mice. *Hepatology*. 2004; 40:1304–1311. [PubMed: 15565662]
165. Sgodda M, Aurich H, Kleist S, Aurich I, König S, et al. Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue in vitro and *in vivo*. *Exp Cell Res*. 2007; 313:2875–2886. [PubMed: 17574236]
166. Taléns-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, et al. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. *World J Gastroenterol*. 2006; 12:5834–5845. [PubMed: 17007050]
167. Theise ND, Krause DS. Bone marrow to liver: the blood of Prometheus. *Semin Cell Dev Biol*. 2002; 13:411–417. [PubMed: 12468241]
168. Zhao DC, Lei JX, Chen R, Yu WH, Zhang XM, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. *World J Gastroenterol*. 2005; 11:3431–3440. [PubMed: 15948250]
169. Zheng JF, Liang LJ. Intra-portal transplantation of bone marrow stromal cells ameliorates liver fibrosis in mice. *Hepatobiliary Pancreat Dis Int*. 2008; 7:264–270. [PubMed: 18522880]
170. Almeida-Porada G, ElShabrawy DPC, Ascensao JL, Zanjani ED. Clonally Derived MSCs Populations are able to Differentiate into Blood Liver and Skin Cells. *Blood*. 2001; 98:abstract.
171. Almeida-Porada G, PCD, Brouard N, Simmons PJ, Ascensao JL, et al. Generation of hematopoietic and hepatic cells by human bone marrow stromal cells in vivo. *Blood*. 2000; 96:570a.
172. Almeida-Porada M, CJ, FA, SPJ, PCD, et al. Intra-Hepatic Injection of Clonally Derived Mesenchymal Stem Cell (MSC) Populations Results in the Successful and Efficient Generation of Liver Cells. *Blood*. 2003; 102:abstract #1229.
173. Chamberlain J, Frias A, Porada C, Zanjani ED, Almeida-Porada G. Clonally derived mesenchymal stem cell (MSC) populations generate liver cells by intra-hepatic injection without the need for a hematopoietic intermediate. *Exp Hematol*. 2003; 32:48.
174. Porada CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. *Adv Drug Deliv Rev*. 2010; 62:1156–1166. [PubMed: 20828588]
175. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. *Curr Stem Cell Res Ther*. 2006; 1:365–369. [PubMed: 18220880]
176. Bosch P, Fouletier-Dilling C, Olmsted-Davis EA, Davis AR, Stice SL. Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. *Mol Reprod Dev*. 2006; 73:1393–1403. [PubMed: 16897738]
177. Bosch P, Stice SL. Adenoviral transduction of mesenchymal stem cells. *Methods Mol Biol*. 2007; 407:265–274. [PubMed: 18453261]
178. Roelants V, Labar D, de Meester C, Havaux X, Tabilio A. Comparison between adenoviral and retroviral vectors for the transduction of the thymidine kinase PET reporter gene in rat mesenchymal stem cells. *J Nucl Med*. 2008; 49:1836–1844. [PubMed: 18984872]
179. Gneocchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. *Methods Mol Biol*. 2009; 482:281–294. [PubMed: 19089363]
180. Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. *Stem Cells*. 2007; 25:220–227. [PubMed: 16960135]

181. Piccoli C, Scrima R, Ripoli M, Di Ianni M, Del Papa B. Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondriadependent cAMP-sensitive reactive oxygen species production. *Stem Cells*. 2008; 26:2843–2854. [PubMed: 18787213]
182. Sales VL, Mettler BA, Lopez-Ilasaca M, Johnson JA Jr, Mayer JE Jr. Endothelial progenitor and mesenchymal stem cell-derived cells persist in tissueengineered patch in vivo: application of green and red fluorescent protein-expressing retroviral vector. *Tissue Eng*. 2007; 13:525–535. [PubMed: 17518601]
183. Fan L, Lin C, Zhuo S, Chen L, Liu N, et al. Transplantation with surviving-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. *Eur J Heart Fail*. 2009; 11:1023–1030. [PubMed: 19875403]
184. Meyerrose TE, Roberts M, Ohlemiller KK, Vogler CA, Wirthlin L, et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. *Stem Cells*. 2008; 26:1713–1722. [PubMed: 18436861]
185. Wang F, Dennis JE, Awadallah A, Solchaga LA, Molter J, et al. Transcriptional profiling of human mesenchymal stem cells transduced with reporter genes for imaging. *Physiol Genomics*. 2009; 37:23–34. [PubMed: 19116247]
186. Xiang J, Tang J, Song C, Yang Z, Hirst DG, et al. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. *Cytotherapy*. 2009; 11:516–526. [PubMed: 19562576]
187. Zhang XY, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. *J Virol*. 2004; 78:1219–1229. [PubMed: 14722277]
188. Zhang XY, La Russa VF, Bao L, Kolls J, Schwarzenberger P, et al. Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. *Mol Ther*. 2002; 5:555–565. [PubMed: 11991746]
189. Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. *Hum Gene Ther*. 2004; 15:1197–1206. [PubMed: 15684696]
190. Stender S, Murphy M, O'Brien T, Stengaard C, Ulrich-Vinther M, et al. Adeno-associated viral vector transduction of human mesenchymal stem cells. *Eur Cell Mater*. 2007; 13:93–99. [PubMed: 17538898]
191. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. *Hematology Am Soc Hematol Educ Program*. 2009
192. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. *Mol Ther*. 2006; 13:1031–1049. [PubMed: 16624621]
193. Persons DA. Lentiviral vector gene therapy: effective and safe? *Mol Ther*. 2010; 18:861–862. [PubMed: 20436489]
194. Altanerova V, Horvathova E, Matuskova M, Kucerova L, Altaner C. Genotoxic damage of human adipose-tissue derived mesenchymal stem cells triggers their terminal differentiation. *Neoplasma*. 2009; 56:542–547. [PubMed: 19728764]
195. Doering CB. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia. *Methods Mol Biol*. 2008; 433:203–212. [PubMed: 18679625]
196. Pipe SW, High KA, Ohashi K, Ural AU, Lillicrap D. Progress in the molecular biology of inherited bleeding disorders. *Haemophilia*. 2008; 14(Suppl 3):130–137. [PubMed: 18510533]
197. Van Damme A, Chuah MK, Dell'accio F, De Bari C, Luyten F, et al. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. *Haemophilia*. 2003; 9:94–103. [PubMed: 12558785]
198. Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. *Hum Gene Ther*. 2001; 12:1527–1541. [PubMed: 11506695]
199. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. *Exp Hematol*. 2001; 29:244–255. [PubMed: 11166464]

200. Nijagal A, Wegorzewska M, Jarvis E, Le T, Tang Q, et al. Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice. *J Clin Invest*. 2011; 121:582–592. [PubMed: 21245575]
201. Peranteau WH, Endo M, Adibe OO, Flake AW. Evidence for an immune barrier after in utero hematopoietic-cell transplantation. *Blood*. 2007; 109:1331–1333. [PubMed: 17023584]
202. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2005; 11:321–334. [PubMed: 15846285]
203. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scand J Immunol*. 2003; 57:11–20. [PubMed: 12542793]
204. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. *Br J Haematol*. 2005; 129:118–129. [PubMed: 15801964]
205. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. *Tissue Eng*. 2006; 12:2263–2273. [PubMed: 16968166]
206. Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood*. 2002; 99:3838–3843. [PubMed: 11986244]
207. Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. *Exp Hematol*. 2005; 33:928–934. [PubMed: 16038786]
208. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood*. 2003; 101:3722–3729. [PubMed: 12506037]
209. Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. *J Immunol*. 2007; 179:2824–2831. [PubMed: 17709496]
210. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. *J Biomed Sci*. 2005; 12:47–57. [PubMed: 15864738]
211. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation*. 2003; 75:389–397. [PubMed: 12589164]
212. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. *Stem Cells*. 2007; 25:2025–2032. [PubMed: 17510220]
213. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood*. 2005; 105:4120–4126. [PubMed: 15692068]
214. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. *J Immunol*. 2006; 177:2080–2087. [PubMed: 16887966]
215. Zhang W, Ge W, Li C, You S, Liao L, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. *Stem Cells Dev*. 2004; 13:263–271. [PubMed: 15186722]
216. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, et al. Human mesenchymal stem cells modulate B-cell functions. *Blood*. 2006; 107:367–372. [PubMed: 16141348]
217. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*. 2005; 105:1815–1822. [PubMed: 15494428]
218. Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the

- differentiation of CD4⁺ T-cell subsets expressing a regulatory/suppressive phenotype. *Haematologica*. 2005; 90:516–525. [PubMed: 15820948]
219. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4⁺ or CD8⁺ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. *Haematologica*. 2007; 92:881–888. [PubMed: 17606437]
 220. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. *Blood*. 2007; 109:228–234. [PubMed: 16985180]
 221. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. *Gene Expr*. 2007; 13:217–226. [PubMed: 17605296]
 222. Nasef A, Mathieu N, Chapel A, Frick J, François S, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. *Transplantation*. 2007; 84:231–237. [PubMed: 17667815]
 223. Hainz U, Jürgens B, Heitger A. The role of indoleamine 2,3-dioxygenase in transplantation. *Transpl Int*. 2007; 20:118–127. [PubMed: 17239019]
 224. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood*. 2004; 103:4619–4621. [PubMed: 15001472]
 225. Jiang W, Ma A, Wang T, Han K, Liu Y, et al. Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. *Pflugers Arch*. 2006; 453:43–52. [PubMed: 16915405]
 226. Jiang W, Ma A, Wang T, Han K, Liu Y, et al. Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. *Transpl Int*. 2006; 19:570–580. [PubMed: 16764636]
 227. Jiang WH, Ma AQ, Zhang YM, Han K, Liu Y, et al. Migration of intravenously grafted mesenchymal stem cells to injured heart in rats. *Sheng Li Xue Bao*. 2005; 57:566–572. [PubMed: 16220194]
 228. Almeida-Porada G, Zanjani ED, Porada CD. Bone marrow stem cells and liver regeneration. *Exp Hematol*. 2010; 38:574–580. [PubMed: 20417684]
 229. Colletti E, Zanjani ED, Porada CD, Almeida-Porada MG. Tales from the Crypt: Mesenchymal Stem Cells for Replenishing the Intestinal Stem Cell Pool. *Blood*. 2008; 112:abstract #390.
 230. Colletti EJ, Airey JA, Liu W, Simmons PJ, Zanjani ED, et al. Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer. *Stem Cell Res*. 2009; 2:125–138. [PubMed: 19383418]
 231. Yamagami T, Colletti E, Wiendl H, Zanjani E, Porada C. Expression of Molecules Involved in Fetal-Maternal Tolerance Allows Human Mesenchymal Stem Cells to Engraft at High Levels across Immunologic Barriers. *Blood*. 2008; 112:3480.
 232. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev*. 2009; 18:683–692. [PubMed: 19099374]
 233. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, et al. Stem cell transplantation: the lung barrier. *Transplant Proc*. 2007; 39:573–576. [PubMed: 17362785]
 234. Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. *Exp Hematol*. 2011; 39:1124–1135. [PubMed: 21906573]
 235. Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. *Blood*. 2006; 107:3859–3864. [PubMed: 16449528]
 236. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. *Blood*. 2000; 95:564–568. [PubMed: 10627463]
 237. Garvey MB. Porcine factor VIII in the treatment of high-titre inhibitor patients. *Haemophilia*. 2002; 8:5–8. [PubMed: 11882075]

238. Hermans C, Owens D, Lilley P, Longo G, Morfini M, et al. Single-dose pharmacokinetics of porcine factor VIII (Hyate C). *Haemophilia*. 2002; 8:33–38. [PubMed: 11882082]
239. Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. *Am J Hematol*. 2001; 67:240–246. [PubMed: 11443636]
240. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, et al. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. *Blood*. 2008; 112:4532–4541. [PubMed: 18716130]
241. Øvlisen K, Kristensen AT, Tranholm M. In vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions. *Haemophilia*. 2008; 14:248–259. [PubMed: 18194311]